Company Overview and News

 
New Strong Sell Stocks for October 19th

16h zacks
Brookfield Infrastructure Partners L.P. (BIP - Free Report) is engaged in utility, transport, energy, and communications infrastructure businesses. The Zacks Consensus Estimate for its current year earnings has been revised 2.2% downward over the last 60 days.
EEFT BIP SND POWI FFIN

 
Hi-Crush Idles Whitehall Plant; Bullish Thesis Unchanged

2018-09-26 seekingalpha
This is not a sign of weakness for frac sand players. On the contrary, it points to the flexibility that HCLP has with its supply chain to navigate temporary slowdowns.
SND HCLP

11
SND / Smart Sand, Inc. 8-K (Current Report)

2018-09-26 sec.gov - 11
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
SND

2
Audentes Therapeutics started at sell with $20 stock price target at B. Riley FBR

2018-09-07 marketwatch - 1
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on ...[...]
BOLD AGFS AGFSW ABEO SND ABEOW

56
5 Penny Stocks You’d Have to Be Crazy to Buy

2018-09-05 investorplace - 4
Whether you’re a newbie who just watched The Wolf of Wall Street or you’re a seasoned trader whose previous fliers on penny stocks have burned one too many holes in your pocket, the story is the same — stay away from penny stocks.
DLPN LWAY SBUX NFLX SND SLCA TYHT FOXA MCD DIS JVA

8
SND / Smart Sand, Inc. 8-K (Current Report)

2018-09-04 sec.gov - 8
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
SND

11
SND / Smart Sand, Inc. 8-K/A (Current Report)

2018-08-30 sec.gov - 11
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
SND

11
SND / Smart Sand, Inc. 8-K (Current Report)

2018-08-28 sec.gov - 11
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SND

19
Sinking Or Swimming A Few Ideas - The Idea Guide

2018-08-18 seekingalpha - 2
Today's Idea Guide looks at a few ideas on companies whose futures seem to be pointed in one direction, to see if the market is right or just overreacting.
HBANN HBANO FIT HBANP LUB GOLF MANU HBAN GPRO ZNGA DRYS VALU AAPL DCIX KHC SND

29
Smart Sand Changes Northern White Narrative

2018-08-14 seekingalpha
Smart Sand is shipping record volumes and posting record income, yet its stock price has severely underperformed peers and the overall market.
APC CKRGZ CHKVP CHKDH CHKVZ HCLP CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI SND AEUA

 
Smart Sand, Inc. (SND) CEO Charles Young on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Good day and welcome to the Smart Sand Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
SND

7
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks - 1
Jounce Therapeutics, Inc. (JNCE - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
JNCE HCCDZ HCHC GWRS UCTI SND RLH UCTT

2
Cable One (CABO) Lags Q2 Earnings Estimates

2018-08-09 zacks
Cable One (CABO - Free Report) came out with quarterly earnings of $7.65 per share, missing the Zacks Consensus Estimate of $7.97 per share. This compares to earnings of $4.97 per share a year ago. These figures are adjusted for non-recurring items.
CABO HCCDZ HCHC GWRS UCTI SND RLH UCTT

2
Nomad Foods (NOMD) Q2 Earnings and Revenues Surpass Estimates

2018-08-09 zacks
Nomad Foods (NOMD - Free Report) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.
HCCDZ HCHC GWRS UCTI NOMD SND RLH UCTT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to SND / Smart Sand, Inc. on message board site Silicon Investor.

Shanda Interactive Entertainment Ltd. (SNDA) Shanda Interactive Entertainment Ltd. (SNDA) Shanda Interactive Entertainment Ltd. (SNDA) SNDK in the new apple iphone 5 SNDK in the new apple iphone 5 SNDK in the new apple iphone 5
QSOUND LABS INC - - QSND - - ACER GROUP - - IBM QSOUND LABS INC - - QSND - - ACER GROUP - - IBM QSOUND LABS INC - - QSND - - ACER GROUP - - IBM SNDT - Sand Technology - A diamond in the sand SNDT - Sand Technology - A diamond in the sand SNDT - Sand Technology - A diamond in the sand
SNDK: SanDisk Corporation SNDK: SanDisk Corporation SNDK: SanDisk Corporation The Round Table: A work by the squares of the SNDK thread. The Round Table: A work by the squares of the SNDK thread. The Round Table: A work by the squares of the SNDK thread.
LEXR vs SNDK LEXR vs SNDK LEXR vs SNDK Ascend Communications (ASND) Ascend Communications (ASND) Ascend Communications (ASND)
SNDK , SSTI , LEXR TA SNDK , SSTI , LEXR TA SNDK , SSTI , LEXR TA SNDK,SSTI,LEXR TA SNDK,SSTI,LEXR TA SNDK,SSTI,LEXR TA
CUSIP: 83191H107